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Abstract: Biodegradable poly(ester amine) (PEA)-based and poly(amido amine) (PAA)-based 
nanoparticles were developed for efficient in vitro siRNA delivery to human umbilical vein 
endothelial cells (HUVECs). They were screened, characterized, and compared with traditionally 
studied DNA-containing particles. Several of the polymeric nanoparticles tested were found to 
be effective for delivering functional siRNA to green fluorescent protein (GFP) + HUVECs, 
achieving 60%–75% GFP knockdown while maintaining high viability. While PEAs have 
been used previously to form polyplexes or nanoparticles for DNA delivery, highly effective 
siRNA delivery in hard-to-transfect human cell types has not been previously reported. PEAs 
and linear nondendrimeric PAAs were also found to be effective for DNA delivery to HUVECs 
using GFP-encoding plasmid DNA (up to 50%–60% transfection efficiency). PEAs and PAAs 
can be separated into groups that form polymeric nanoparticles effective for siRNA delivery, 
for DNA delivery, or for both.
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Introduction
Delivery of siRNA and DNA is an attractive option for a variety of applications, from 
basic science research to potential clinical use. The ability to either induce or reduce 
expression of specific genes in vitro may lend itself to cell differentiation or guidance 
for regenerative medicine.1,2 Aberrant expression of genes has also been found to play 
an important role in many diseases.3,4 The ability to mimic these pathological states 
could be useful for basic studies in a laboratory setting, while the ability to reverse 
those states has potential for clinical use in curing or ameliorating specific diseases5–10 
or for promoting tissue repair.11
Human umbilical vein endothelial cells (HUVECs) are a particularly suitable model 
cell in which to study these effects. HUVECs and related cells have high relevance 
in the fields of tissue engineering,12,13 cancer therapy,14,15 and other conditions with 
altered angiogenesis.16,17 Importantly, upregulation of proangiogenic genes may be 
crucial for tissue engineering to allow nutrient and gas transfer throughout a construct.18 
The opposite effect would be necessary for the treatment of diseases like cancer19 
or macular degeneration,20 in which excess angiogenesis or neovascularization is a 
cause of pathology.21 The ability to deliver either siRNA or DNA to these and other 
cell types would allow the flexibility to alter gene expression in either case. While 
siRNA and DNA molecules are chemically similar and share the ability to complex 
with polymeric nanoparticles via electrostatic interactions, their mechanisms of action 
and intracellular targets are different; siRNA acts primarily in the cytoplasm while International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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DNA must reach the nucleus,22 providing distinct challenges 
in the delivery of each via transfection agents.
Many attempts to improve delivery of nucleic acids have 
relied on viruses which, while efficient, are limited to small 
cargo sizes and are much more likely to cause insertional 
mutagenesis, an immune response, or severe systemic 
  toxicity.23 Attempts to improve siRNA delivery technologies 
include lipid-based formulations24 and emulsion particles 
using mixtures of polymers or biomaterials.25,26 Still, effi-
ciency must be improved before translating this technology 
to the clinic. Natural and synthetic cationic polymers have 
been previously studied because they are potentially safer 
and easier to manufacture,27,28 but nondegradable polymers 
like poly(ethyleneimine) suffer from high toxicity,29 which 
correlates with high molecular weight.30 Although polymeric 
gene delivery has been traditionally less efficient than virus-
mediated gene transfer,31 members of one class of polymers, 
ie, poly(ester amine)s, have been found to be very effective 
in DNA delivery to a number of cell types while causing less 
toxicity than leading commercially available transfection 
reagents,32–34 likely due to the ability of polymers to degrade 
under physiological conditions and their theoretically unlim-
ited variation in structure and properties, providing the flex-
ibility to choose a polymer structure based on the particular 
purpose for which it is best suited.
Here, we expand upon the methods and chemical moieties 
that have in the past been used in gene delivery35 to identify 
poly(ester amine)s (PEAs) and poly(amido amine)s (PAAs) 
from a chemically diverse library that could complex well with 
either siRNA, plasmid DNA, or both. In particular, PEAs in 
this form have not been previously shown to enable effective 
siRNA delivery. With new polymer structures and formulation 
conditions, we show here that they are not only effective but 
also superior to the leading commercially available reagent, 
Lipofectamine™ 2000. After formation and characterization, 
the polymer-nucleic acid nanoparticles were used to deliver 
bioactive siRNA and DNA to HUVECs, and their effectiveness 
in both applications was compared. The goals of this study were 
to determine if small changes to the polymer structure could 
tune the efficacy of a polymeric nanoparticle for nucleic acid 
delivery and to determine any relationships between physico-
chemical properties and transfection efficiency profiles.
Materials and methods
Materials
Monomers for polymer synthesis (Figure 1) were   purchased 
from Alfa Aesar (Ward Hill, MA) [1,4-butanediol diacrylate 
(B4),  N,N′-bis(acryloyl)cystamine  (BSS), 
3-amino-1-propanol (S3), 4-amino-1-butanol (S4), 
5-amino-1-pentanol  (S5),  1-(3-aminopropyl)-4- 
methylpiperazine (E7), cystamine   dihydrochloride (E10)], 
Fluka (Milwaukee, WI) [2-(3-aminopropylamino)ethanol 
(E6)], Monomer-Polymer and Dajac Labs (Feasterville, PA) 
[1,5-pentanediol diacrylate (B5)], Sigma Aldrich (St Louis, 
MO) [1,3-diaminopropane (E1)], and TCI America (Chicago, 
IL) [1,3-diaminopentane (E3), 2-methyl-1,5-diaminopentane 
(E4)]. HUVECs and endothelial growth medium-2 (EGM-2) 
were purchased from Lonza (Walkersville, MD) and used as 
recommended. Plasmid pDsRed-Max-N1 DNA (Addgene 
plasmid 21718,36 Cambridge, MA) was amplified by   Aldevron 
(Fargo, ND), and siRNA against eGFP with 5′-CAAGCU-
GACCCUGAAGUUCTT (sense) and 3′-GAACUUCAGG-
GUCAGCUUGCC (antisense) (Silencer® positive control) 
and a scrambled siRNA sequence with 5′-AGUACUGC-
UUACGAUACGGTT (sense) and 3′-CCGUAUCGUAAGCA-
GUACUTT (antisense) (Silencer® negative control 1) were 
designed by and purchased from Ambion Inc (Carlsbad, CA). 
Lipofectamine 2000 and   Opti-MEM I were from Invitrogen 
(Carlsbad, CA) and used according to the manufacturer’s 
instructions. All other   materials used were reagent grade.
Polymer synthesis
The specific monomers used in this study were chosen 
in order to sample varied parts of a large chemical space 
while maintaining structural similarities between the back-
bone, sidechain, and endgroup monomers utilized. PEAs 
were   synthesized as previously reported.34,37,38 Briefly, one 
Figure  1  Monomer  structures  used  to  synthesize  polymers.  Backbone  (B) 
monomers were polymerized with sidechain (s) monomers. The B-s base polymers 
were then endcapped with small molecules (e).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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diacrylate backbone monomer (B) was mixed with one 
amine-containing sidechain (S) at 1.2:1 or 1.05:1 ratio and 
stirred overnight at 90°C. Acrylate-terminated B-S base 
polymers resulted from Michael addition of amines to the 
acrylate groups. Each base polymer was dissolved in dimethyl 
sulfoxide (DMSO) at 167 mg/mL; 480 µL of base polymer 
solution was mixed with 320 µL of a solution of one endcap 
monomer (E) in DMSO at 0.5 M, and the mixture was shaken 
for 24 hours at room temperature. Endcapped polymers were 
stored at 4°C as 100 mg/mL solutions in DMSO. For PAA 
synthesis, backbone monomer BSS was mixed with a side-
chain (S) monomer at 200 mg/mL in DMSO, stirred overnight 
at 90°C, and endcapped as described above. The polymers 
are described henceforth by their constituent monomers, eg, 
the copolymer of B4 and S5 (B4-S5) can be endcapped with 
E6, then abbreviated as B4-S5-E6, or 456.
Polymer degradation
To ensure that the polymers used in this study were degrad-
able under mild and physiological conditions, polymers were 
dissolved in 1× phosphate-buffered solution at 20 mg/mL. 
The polymer solutions were agitated using a shaker at 37°C. 
At various time points, 20 mL were removed, the pH was 
measured, and the samples were snapfrozen and lyophilized. 
Three sample replicates were analyzed at each time point. 
The samples were reconstituted in butylated hydroxytoluene-
stabilized tetrahydrofuran with 5% DMSO and 1% piperi-
dine, filtered through a 0.2 µm filter, and measured with gel 
permeation chromatography (Waters, Milford, MA).
Nanoparticle preparation
A 0.18 µM (2.7 µg/mL) solution of siRNA in sodium acetate 
buffer (25 mM, pH 5) or 60 µg/mL plasmid DsRed-Max DNA 
in sodium acetate was prepared. Polymer was diluted in sodium 
acetate at various weight/weight (w/w) ratios, then added at a 
1:1 volume ratio to the nucleic acid solution. The complexes 
were mixed by pipetting and incubated at room temperature for 
10 minutes to allow complexation and were used immediately.
Nanoparticle characterization
After 10 minutes, the suspension of complexed nanoparticles 
was diluted in 1× phosphate-buffered solution to a final con-
centration between 108 and 109 particles/mL and measured 
by nanoparticle tracking analysis using a NanoSight LM10. 
Three samples were prepared and measured for each condition. 
When using normalized concentration values, samples were 
normalized to the amount (mass) of nucleic acid rather than 
to the number of particles in order to keep the amount of the 
bioactive agent constant when comparing groups. Particles 
were also imaged by transmission electron microscopy (TEM) 
using a Phillips/FEI BioTwin CM120. For TEM, nanoparticle 
suspensions without stain were adsorbed onto carbon-coated 
copper grids, which were allowed to dry overnight before imag-
ing. For zeta potential analysis, nanoparticles were prepared 
as described above, then diluted in 1× phosphate-buffered 
solution. The diluted particles were measured by dynamic 
light scattering using a Nano Series zetasizer (Malvern, 
Worcestershire, UK) at a final concentration of 5 µg/mL.
Gel retardation assays were carried out by adding poly-
mer of varying concentrations in sodium acetate buffer to a 
constant concentration of DNA or siRNA in sodium acetate, 
similar to the normal particle preparation protocols described 
above. After 10 minutes of incubation, a solution of 30% 
glycerol in water was added in a 1:5 volumetric ratio as a load-
ing buffer. Bromophenol blue or other dyes were not added, 
because they were found to interfere with binding. Samples 
were loaded into 1% agarose gel with 1 µg/mL ethidium 
bromide at 125 ng DNA or siRNA per well. Samples were 
run for 15 and 30 minutes for siRNA and DNA, respectively, 
under 100 V , then visualized using ultraviolet exposure.
Transfection of hUVecs
HUVECs were stably transduced using a lentiviral pPT-eGFP 
plasmid vector (cytomegalovirus promoter). For siRNA 
transfections, the cells were seeded at 13,000 cells/cm2 in 
96-well plates in complete EGM-2 and allowed to adhere 
overnight. Then, siRNA against eGFP or a scrambled control 
sequence was diluted in sodium acetate buffer (25 mM, pH 5). 
Polymers were diluted in sodium acetate buffer and combined 
with each of the GFP (green fluorescent protein)-siRNA 
and the control scrRNA at 60, 100, or 150 w/w. After ten 
minutes, nanoparticle complexes were added directly to the 
cells in medium at a final volume ratio of 1:5 nanoparticles to 
medium and a final siRNA concentration of 60 nM per well. 
As a positive control, Lipofectamine 2000 complexes were 
prepared in Opti-MEM I according to the manufacturer’s 
instructions and were added to the wells at the same final 
siRNA concentration as the experimental polymer groups. 
After 4 hours of incubation, the particles were aspirated and 
the medium replaced with fresh EGM-2.
Viability was assessed 24 hours after transfection using an 
MTS assay (CellTiter AqueousONE, Promega, Madison, WI) 
according to the manufacturer’s protocol. On each day 
  following transfection, the amount of GFP present in each well 
was measured with a fluorescence plate reader (Synergy 2, 
Biotek, Seattle, WA). After three days, cells were imaged International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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with a Zeiss Observer A.1, then trypsinized, resuspended 
in phosphate-buffered solution with 2% fetal bovine serum, 
and measured with an Accuri C6 flow cytometer equipped 
with an Intellicyt high-throughput loader and reader. The 
geometric mean of the eGFP signal measured with emission 
at 530/30 nm was calculated for untreated cells, cells treated 
with GFP-siRNA, and cells treated with scrRNA. Nonspecific 
autofluorescence of each sample at 530/30 nm emission was 
subtracted using GFP-positive HUVECs of the same lot and 
passage number that underwent the same treatment with 
polymer-siRNA nanoparticles. The geometric mean GFP 
signal per cell for each polymer-siRNA sample was normal-
ized to the GFP signal per cell in polymer-scrRNA control 
samples. FlowJo was used for flow cytometry analysis.
For DNA transfections, HUVECs were seeded at 
26,000 cells/cm2 in 96-well plates in complete EGM-2 and 
allowed to adhere overnight. DNA polymer nanoparticles 
were prepared as previously described. Briefly, plasmid 
DsRed-Max and polymer were each separately diluted in 
25 mM sodium acetate, then mixed at a 1:1 volume ratio for 
a polymer-to-DNA w/w ratio of either 30, 60, or 90. After 
ten minutes, nanoparticles were added directly to the cells in 
medium, at a final volume ratio of 1:5 nanoparticles to medium 
and a final DNA concentration of 5 µg/mL per well. Viability 
was assessed 24 hours after transfection using an MTS assay. 
After 48 hours, the cells were trypsinized and resuspended 
in phosphate-buffered solution with 2% fetal bovine serum. 
Transfection efficiency was assessed using flow cytometry, 
with DsRed emission in the 580/40 nm channel.
statistics
Comparisons between GFP-siRNA and scrRNA within the 
same polymer were done using the Student’s t-test.   Comparisons 
across multiple groups of siRNA or DNA treatment conditions 
were done using one-way analysis of variance with a post hoc 
Dunnett’s test to assess significance compared with the Lipo-
fectamine 2000-positive control group. Significance is shown 
as *P , 0.05, **P , 0.01, or ***P , 0.001 unless otherwise 
stated. All graphs show mean ± standard error of the mean 
unless otherwise stated. All the transfection experiments (DNA 
or siRNA) were performed in quadruplicate and all the sizing/
zeta potential experiments (nanoparticle tracking analysis or 
dynamic light scattering) were performed in triplicate.
Results and discussion
Polymer characterization
Both types of polymers used in this study are biodegradable, 
which is essential to release nucleic acid intracellularly and 
prevent toxicity; PEAs degrade by hydrolysis and PAAs by 
bioreduction in the reducing cytosolic compartment. Polymer 
structures selected for this study were among those previ-
ously used for DNA delivery,39 as well as some additional 
structures used in preliminary optimization studies for siRNA 
delivery to human cells.
The polymers tested were shown to degrade under mild 
and physiologically relevant conditions by using representative 
PEAs 447 and 537, with an initial number-weighted molecular 
weight (Mn) of 7152 Da and 4759 Da, respectively. By gel 
permeation chromatography analysis, both polymers degraded 
fully, defined as having an Mn less than twice the molecular 
weight of one backbone repeat unit within 24 hours in an aque-
ous buffer solution (Figure 2). After 72 hours, the Mn of 447 
and 537 was 450 ± 12 Da and 390 ± 47 Da, respectively.
characterization of DNA and sirNA 
nanoparticles
The ability of PEAs and PAAs to condense nucleic acids into par-
ticles was measured by nanoparticle tracking analysis, whereby 
the size of each individual particle in a sample is measured 
based on its rate of diffusion. This is in contrast with dynamic 
light scattering, which, while having certain advantages, is often 
poorly suited for analysis of polydispersed distributions. Because 
nanoparticle tracking analysis directly calculates number-
weighted size measurements, size distributions should be less 
biased toward small numbers of large particles or aggregates. 
The validity of the results was determined by TEM.
The mean   ± standard error of the mean is shown for 
the number-weighted mean and mode particle hydro-
dynamic diameter for both DNA and siRNA particles 
(Figure 3A and B). Particle concentration, normalized to the 
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Figure 2 Polymers 447 and 537 degraded readily in an aqueous buffer solution 
when incubated with agitation at 37°c.
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amount (µg) of siRNA or DNA in each sample, is shown in 
Figure 3C and D and the zeta potential in Figure 3E and F.
Given that the cationic polymers form nanoparticles with 
nucleic acids via electrostatic interactions, it is not surpris-
ing that similar trends are seen between siRNA and DNA 
particles; those polymers that can condense DNA efficiently 
into particles that remain stable in a solution of salt buffer 
also tend to be effective in forming siRNA particles. Most of 
the particles fall within the range of 50–150 nm in diameter, 
which has been shown to be a range in which particles are 
easily taken up by cells for nucleic acid delivery.40 However, 
we hypothesized that there would be significant differences 
between some of the DNA-containing and siRNA-containing 
particles due to the diversity in polymer structures and 
nanoparticle formulation ratios that we have used. Our 
results indicate this to be the case. Some polymers that 
complex well with DNA at 30 w/w (eg, 453) form very few 
particles with siRNA at low or moderate amounts of polymer 
(,90 w/w). The small size and low concentration of particles 
formed between siRNA and 453 at 60 w/w indicates that free 
polymer remains in solution and, being amphiphilic, may 
simply dissolve in water rather than   participate in particle 
formation, as it does at higher concentrations. While this 
polymer forms many particles with DNA at low w/w, it also 
has a larger mean and mode particle size in those conditions, 
which may indicate instability of the nanoparticle complexes. 
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Figure 3 The mean and mode diameter of measured particles is shown in (A) sirNA and (B) DNA. The concentration of particles formed under these conditions is shown 
in (C) sirNA and (D) DNA. The zeta potential in 1× phosphate-buffered solution is shown in (E) sirNA and (F) DNA.
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Therefore, it may be possible to correlate cationic polymer 
efficiency in DNA complexation with its efficiency in siRNA 
complexation.
Small changes in the chemical structure of a polymer, 
such as the use of different endgroups, sometimes caused 
a drastic change in the properties of the resulting particles. 
For example, starting with the same base polymer B5-S3, 
modification with the E10 endgroup formed particles that 
were small in size (about 80 nm for both DNA and siRNA), 
whereas modification of B5-S3 with the E7 endgroup formed 
larger particles (about 300 nm for DNA and about 200 nm for 
siRNA). Similarly, with the B4-S5 base polymer, even the 
single-carbon difference between the endgroups E3 and E4 
caused a difference in size. Surface charge or zeta potential 
similarly showed that small changes in structure could affect 
particle properties (Figure 3E and F). As expected, all the 
particle formulations studied here had a positive surface 
charge due to the cationic polymers, ranging from 1–20 mV 
when suspended in phosphate-buffered solution. The zeta 
potentials of particles formed with siRNA were generally 
similar to that of particles formed with DNA. Although only 
a relatively small number of structures were explored in this 
study, these results suggest that further work on a larger 
group of polymers could be useful to understand better the 
relationship between the chemical structure and properties of 
the resulting particles. Of particular interest is the potential 
to correlate the particle-forming capability of a polymer with 
its transfection efficiency.
In general, siRNA required a higher polymer-to-nucleic 
acid w/w ratio for effective electrostatic complexation than 
plasmid DNA. This may be due to the high multivalency/
avidity of plasmid DNA, which has over 200-fold more 
negatively charged phosphate groups per molecule than 
siRNA. Differences in particle formation efficiency were also 
observed using gel electrophoresis. DNA movement through 
the gel was completely stopped even at the lowest w/w tested 
(20 w/w), while some polymers, like 447, needed to be in 
higher concentration for siRNA, which is not fully retarded 
until 60 w/w 447 is added (Figure 4).
TEM was used qualitatively to visualize the nanopar-
ticles (Figure 5). The particles appeared approximately 
spherical. Crucially, the trends in size and distribution found 
using nanoparticle tracking analysis were also seen in TEM 
micrographs, verifying that this method gave accurate size 
distributions. It is expected that TEM measurements would 
be slightly smaller, as nanoparticle tracking analysis mea-
sures the hydrodynamic diameter while TEM shows dry 
particles; however, trends should remain similar regardless 
of the measurement modality. For example, nanoparticles 
of siRNA complexed with PEA 5310 at 60 w/w had a mean 
diameter of 105 ± 13 nm, measured by nanoparticle tracking 
analysis, while DNA nanoparticles with PEAs 453 and 537 at 
60 w/w had mean diameters of 100 ± 5 nm and 338 ± 15 nm, 
respectively. TEM images showed the same trends, with 
mean diameters of 61 ± 10, 93 ± 16, and 190 ± 31 nm for 
siRNA-5310, DNA-453, and DNA-537, respectively.
To verify that the trends in Figure 3 were not due simply 
to the inherent tendency of the polymers to aggregate in 
aqueous medium, sizing studies were repeated on a subset 
of the polymers using the same procedure and concentrations 
as for siRNA particles above, but without any nucleic acid 
(polymer only). Most of the tested polymers that appeared 
to complex well with nucleic acid based on concentration 
and size distribution, such as 454 and 447, were also found 
to form several-fold more particles when complexed with 
siRNA than they did on their own (Figure 6A). Interestingly, 
some polymers, like 5310, and Lipofectamine 2000 showed 
no statistically significant difference in the number of par-
ticles formed either alone or when complexed with siRNA. 
However, Figure 6B does show a slight shift in the peak   
A
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Figure 4 Poly(ester amine) 453 fully retards both DNA and sirNA at 20 w/w or lower, (A and B) 447 fully retards DNA, but up to 60 w/w is needed for sirNA retardation 
(C and D). 
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particle diameter between 5310 or Lipofectamine alone and 
in complex with siRNA, which may indicate that those par-
ticles formed with siRNA are different from those formed 
simply via self-assembly of amphiphilic molecules in aque-
ous medium with no siRNA.
sirNA transfection of hUVecs
HUVECs stably expressing eGFP were transfected with 
siRNA-polymer nanoparticles. The measured GFP signal 
over time was compared with that of cells treated with 
scrRNA-polymer nanoparticles, because preliminary work 
had shown that this was an accurate measure of the amount 
of GFP in each well (see Figure S1). Selected polymers, as 
well as positive and negative controls, are shown in Figure 7. 
Background fluorescence was measured from GFP cells in 
medium and was subtracted from all other readings. Percent 
knockdown was calculated by normalizing GFP fluorescence 
from the GFP-siRNA-treated cells to the scrRNA-treated 
cells. In groups that received either no treatment, treatment 
with only siRNA, or treatment with polymer complexed with 
scrRNA, the GFP signal increased over time as the HUVECs 
proliferated. In groups treated with GFP-siRNA complexed 
with certain polymers (453, 454, 456, 447, and Lipofectamine 
2000), the GFP signal decreased compared with the controls. 
The difference between cells treated with GFP-siRNA and 
scrRNA was statistically significant (P , 0.05) for the poly-
mer formulations shown in Figure 7.
The decrease in average GFP signal per cell three 
days after transfection is shown in Figure 8. Cell counts 
and viability were not statistically different between the 
GFP-siRNA and scrRNA groups. However, flow cytometry 
analysis showed an increase in the 530 nm emission per cell 
in some of the groups treated with the scrRNA-polymer 
control. This increase was statistically significant com-
pared with the untreated groups (P , 0.05) for polymers 
454 (150 w/w), 5310 (100 w/w), 447 (100 and 150 w/w), 
and SS41 (150 w/w). Because it was accompanied by a 
  corresponding increase in emission at 580 nm, this was 
considered to be increased autofluorescence due to treat-
ment with certain polymers. This increased autofluorescence 
was not correlated with cell cytotoxicity (.90% viability 
for SS41 at 150 w/w and approximately 80% viability for 
447 at 100 w/w). For analysis, the reported knockdown 
was calculated by comparing GFP-siRNA groups with 
scrRNA groups using the same polymer. Importantly, there 
were some polymer formulations that showed efficient 
knockdown, high viability, and no significant change in 
autofluorescence due to treatment. Polymers 453, 454, 
5310, 456, and 447 and Lipofectamine all showed sta-
tistically significant (one-way analysis of variance, post 
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concentration of 454 is increased, this is accompanied by 
high toxicity as well, showing that the formulation must be 
optimized for safe as well as effective delivery.
DNA transfection
Experiments done with siRNA-polymer nanoparticles were 
repeated with plasmid DsRed-Max DNA by slightly modify-
ing the particle fabrication method described earlier. Optimal 
polymer-to-DNA ratios were found to lie between 30 and 
90 w/w (preliminary data not shown), and DsRed expression 
was measured using flow cytometry two days after transfection. 
Figure 9 shows the siRNA knockdown   efficiency (up to 
72.3% ± 0.6%) and DNA transfection   efficiency (up to 
59.7% ± 2.0%) for all tested polymers at the optimal w/w 
ratio found for each polymer. As with the   nanoparticle sizing 
study, many of the polymers that are efficient for delivery of 
one type of nucleic acid also work in delivery of the other, 
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although the optimal polymers for delivery of each type of 
nucleic acid were found to differ slightly.
Fluorescence imaging suggested relatively high trans-
fection using Lipofectamine 2000 after 24 hours, as seen in 
Figure 9B. However, there was also high toxicity, as evident 
in the image, which likely explains the low measurement of 
transfection efficiency from flow cytometry. On the other 
hand, many of the PEAs used caused significantly higher 
transfection after 48 hours with much lower nonspecific 
toxicity.
Interestingly, the polymers that formed the best nanopar-
ticles with a mean and mode diameter of 50–150 nm and high 
concentration of formed particles also tended to be among 
those that were very efficient in nucleic acid delivery. As 
seen in Figure 10A and B, there is a narrow range of sizes 
within which nanoparticles are effective. The one polymer 
in both the siRNA and DNA groups that did not fit the 
trend was 537 at 100 w/w and 90 w/w, respectively, and 
showed moderate efficacy despite its large size. However, 
both   nanoparticle tracking analysis and TEM showed that 
537 forms a polydispersed population of nanoparticles with 
siRNA and DNA, suggesting that a subpopulation of smaller 
particles may be able to interact with and transfect cells, 
while larger particles are less effective and therefore cause 
the lower overall efficiency seen using the polymer. These 
graphs suggest that an optimal size may be necessary but not 
sufficient for effective transfection.
Some of the differences in delivery efficacy may be 
explained by differences in particle concentration. While all 
experimental conditions have the same dose of nucleic acid, 
the number of individual particles that self-assemble with 
this constant amount of nucleic acid varies with polymer 
structure. The particle concentration may be indicative of 
the efficiency with which polymers are able to complex their 
nucleic acid cargo. Figure 10C and D show that there is a 
small positive correlation between the number of nanoparti-
cles per dose and siRNA knockdown efficiency (r2 = 0.4678) 
or DNA transfection efficiency (r2 = 0.4344). Interestingly, 
this trend is more easily apparent in the siRNA particles, 
since some DNA particles were able to achieve moderate 
to high transfection at a relatively low number of particles 
per dose. This suggests that, with the polymers tested, fewer 
particles may be needed for effective DNA delivery than for 
siRNA delivery.
Similarly, dynamic light scattering was used to measure 
the zeta potential of polymer-nucleic acid complexes and 
showed some slight trends as well. The increasing transfec-
tion efficacy with zeta potential is visible for siRNA nano-
particles with r2 = 0.4905; while DNA transfection generally 
increases with zeta potential, the correlation is less clear 
with a correlation coefficient of only r2 = 0.2427 (Figure 11). 
Transfection efficiency is expected to be dependent on mul-
tiple factors and all of these physicochemical properties must 
be taken into account when designing effective polymers for 
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nucleic acid delivery. These studies reveal the complexity 
of PEA and PAA nanoparticle systems wherein there is not 
a single parameter that defines transfection efficiency. Here, 
we show quantitatively the correlation of particle size, zeta 
potential, and concentration on transfection efficacy over a 
range of different polymer types, as well as demonstrating 
the likely effect of polymer structure.
It is also interesting to note the differences in trends 
observed for DNA delivery compared with siRNA delivery. 
For example, with the B4-S5 base polymer, the E4 endgroup 
nanoparticles have smaller size compared with the E3 
endgroup nanoparticles, and the smaller 454 nanoparticles 
are more effective for siRNA delivery than 453, although 
their DNA delivery is comparable. Similarly, the base 
polymer B5-S3 formed different particles depending on its 
endgroup, which was reflected in the degree of success of 
  transfection. The relatively large nanoparticles formed with 
the 537   polymer are more effective for DNA delivery while 
having only a moderate effect when using siRNA.
However, comparison with another B5-S3 polymer, 
5310, makes it clear that several factors in combination are 
likely to dictate the success of transfection. The smaller 
particles formed with 5310 were expected in part to be due 
to the positive charge of the E10 endgroup and the relatively 
high positive zeta potential of 5310. While these particles 
were moderately effective for siRNA delivery, with up 
to 52.5% ± 1.7% knockdown in the best formulation, it 
was one of the least efficient polymers for DNA delivery 
(7.0% ± 1.2% of cells transfected). The opposite is true 
of 456, which was the most effective for DNA delivery 
(59.7% ± 2.0%) and only moderately effective for siRNA 
delivery, even though the particles it formed were similar 
in concentration, size distribution, and surface charge com-
pared with other less effective polymers. The biochemical 
properties of these polymers, including their endgroups and 
degradation mechanisms, must also play an important role 
in determining nanoparticle efficacy. It is important to note 
that the intracellular targets and effects are not the same for 
siRNA and DNA delivery; the latter must enter the nucleus 
intact and be able to be transcribed for protein production, 
while the former acts primarily in the cytoplasm. The initial 
barriers are expected to be similar in these two cases, with 
nucleic acid-polymer particles entering the cell via endocy-
tosis or macropinocytosis and then escaping the endosomal 
compartment to be trafficked through the cytoplasm. In 
addition to the differences in particle formation capacity 
shown in this study, it is possible that certain PEAs or PAAs 
are better suited for intracellular steps downstream from 
initial internalization and endosomal escape. For example, 
it is possible that the cytosolic mechanism of action of 
siRNA makes quick polymer degradation or nucleic acid 
release more crucial than in DNA delivery, where slower 
degradation could protect the plasmid for a longer time as 
it is trafficked towards the nucleus. In particular, based on 
our observations in this study, we hypothesize that E10-
terminated polymers, a newly developed structure, may have 
improved efficacy for siRNA compared with DNA due to the 
presence of disulfide bonds that can enable quicker release 
of nucleic acid cargo to the cytoplasm.
Formulation parameters were found to be extremely 
important in transitioning from DNA to siRNA delivery. 
Although more polymer per nucleic acid residue was needed 
in these studies for siRNA delivery than for DNA delivery, 
because the molecular weight of siRNA is so much smaller 
than that used for the DNA transfections, the total mass of 
nucleic acid, and therefore the total amount of polymer added 
to cells in siRNA transfections, was still less than that used 
for DNA. In the literature, PEA-siRNA nanoparticles were 
found to be unable to transfect HeLa cells without the use 
of gold nanoparticles as a scaffold,41 and other groups using 
similar systems report less knockdown than that described 
here, or used higher siRNA doses of up to 125 nM, usually 
in the absence of serum in their transfection media.42,43 It 
is likely that the higher weight ratios used in the present 
study (100–150 w/w) as well as the ability to screen several 
distinct molecular entities enabled our enhanced efficacy, 
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which highlights the importance of different fabrication 
conditions for nanoparticle self-assembly to encapsulate 
DNA versus siRNA.
It is encouraging that some formulations, such as 454 at 
100 w/w and 456 at 150 w/w, are able to cause significant 
knockdown while maintaining 80% viability or greater, 
reflective of the mild nature of these reagents compared with 
other commonly studied materials for siRNA delivery. For 
example, many efforts toward efficient siRNA delivery have 
used lipid-based formulations, such as the Lipofectamine 
2000 used here as a point of comparison. However, 
these may be highly cytotoxic44 and exhibit low colloidal 
stability.45 A cationic polymer commonly studied for nucleic 
acid delivery, polyethyleneimine, also shows high toxicity 
and often must be chemically modified to ameliorate this 
before use,46 as well as requiring high doses for effective 
knockdown.47 Other studies using nonlipid formulations, 
like exosomes48 or gold nanoparticle immobilization,49 have 
also used much higher in vitro siRNA concentrations of 
up to 200 nM to achieve similar knockdown to the 60 nM 
reported here, while also using easier-to-transfect cell types 
like CHO-K1 or HeLa cells. It has also been speculated that 
surface adsorption or conjugation methods, while fairly 
effective, may have lower efficiency because of the reduced 
availability of immobilized siRNA.50 Some siRNA delivery 
systems require added heat or chemicals during synthesis45,51 
that can be potentially destructive to siRNA. In contrast, the 
method described here allows for quick, simple complex-
ation under mild conditions.
Conclusion
Here, we report for the first time that synthetic PEA-siRNA 
self-assembled nanoparticles are effective for siRNA delivery 
and show significant knockdown of HUVECs at relatively 
low doses of siRNA. We also report end-modified PAAs 
capable of more modest intracellular nucleic acid delivery. 
Experiments with nanoparticles containing siRNA resulted 
in up to 60%–75% knockdown in HUVECs after 3 days. 
Maximum DNA delivery with these polymeric nanoparticles 
caused transgene expression in 59.7% ± 2.0% of HUVECs 
after 2 days. Importantly, different parameters may be most 
crucial for each type of nucleic acid cargo. A high nanopar-
ticle formation efficiency and a size distribution centered near 
100 nm appeared necessary but not sufficient for successful 
transfection. In general, higher weight ratios of polymer 
to nucleic acid (100–150 w/w) were required for siRNA-
containing nanoparticles versus nanoparticles formed with 
plasmid DNA (30–90 w/w).
While there were some polymers that were similarly 
effective in delivering both types of nucleic acids, other 
polymers delivered one type of nucleic acid well but 
were fairly ineffective in delivering the other. This raises 
the possibility that some of these cationic polymers may 
be able to deliver multiple DNA and siRNA molecules 
together simultaneously within the same nanoparticles. 
In another strategy, specialized polymers optimized for 
the delivery of only one type of nucleic acid may be more 
efficient for a certain application. While these results 
were shown in HUVECs, a difficult-to-transfect human 
primary cell type with many potential applications in tissue 
engineering and drug delivery, it is expected that these 
nanoparticles would be effective for delivery to other cell 
types as well.
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Figure  S1  gFP+  hUVecs  were  seeded  in  96-well  plates  at  known  densities 
and allowed to settle and adhere for 1 hr before measuring fluorescence with a 
microplate reader. Linear regression showed a positive, linear correlation following 
the relation rFU = 33073*(#cells)+6599 with correlation coefficient r2 = 0.985. The 
gray, shaded region shows the 95% confidence interval of the regression line. 
Note: error bars represent standard deviation of multiple replicates at each cell 
density.
Abbreviations: gFP, green fluorescent protein; HUVECs, human umbilical vein 
endothelial cells; RFU, relative fluorescence units.
Supporting figure